Zobrazeno 91 - 100
of 22 454
pro vyhledávání: ''
Autor:
Sang Hoon Ahn, Soo-Young Park, Yeon Seok Seo, Won Young Tak, Yun Ho Roh, Mi Na Kim, Han Ah Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Beom Kyung Kim, Young Eun Chon, Hye Won Lee
Publikováno v:
Journal of Gastroenterology and Hepatology. 37:200-207
BACKGROUND AND AIM Antiviral therapy (AVT) induces fibrosis regression in patients with chronic hepatitis B. We investigated long-term effects of entecavir (ETV) versus tenofovir (TDF) on fibrotic burden. METHODS Treatment-naive chronic hepatitis B p
Autor:
Stuart C. Gordon, Joseph A. Boscarino, Jennifer Vincent, Jia Li, Keith D. Lindor, Robert J. Romanelli, Sheri Trudeau, Fold Investigators, Jeffrey J. VanWormer, Christopher L. Bowlus, Amandeep Sahota, Heather Anderson, Yihe G. Daida, Carla Rodriguez-Watson, Loralee B Rupp, Christina Melkonian, Kuan-Han Hank Wu, Yueren Zhou, Mei Lu, Mark A Schmidt, Irina V. Haller
Publikováno v:
Digestive Diseases and Sciences. 67:4170-4180
Ursodeoxycholic acid (UDCA) remains the first-line therapy for primary biliary cholangitis (PBC); however, inadequate treatment response (ITR) is common. The UK-PBC Consortium developed the modified UDCA Response Score (m-URS) to predict ITR (using a
Autor:
Mitsuhiro Shikamura, Yasuo Suzuki, Makoto Naganuma, Toshifumi Hibi, Jovelle Fernandez, Satoshi Motoya, Mamoru Watanabe, Takanori Kanai, Lyann Ursos, Tetsuharu Hori, Kenji Watanabe, Haruhiko Ogata, Shigeru Sakamoto, Toshiyuki Matsui
Publikováno v:
Journal of Gastroenterology and Hepatology. 37:81-88
BACKGROUND AND AIM This study aimed to determine the efficacy and safety of vedolizumab treatment with or without concomitant immunomodulator use in Japanese patients with moderate-to-severe ulcerative colitis. METHODS Among enrolled patients in a ph
Autor:
Kavel H. Visrodia, Jeffrey W. Clark, Thomas E. Clancy, David P. Ryan, Kumar Krishnan, Aparna Raj Parikh, Motaz Qadan, Andrew L. Warshaw, Douglas A. Rubinson, Lipika Goyal, Carlos Fernandez-del Castillo, Keith D. Lillemoe, Yasmin G. Hernandez-Barco, Vishwajith Sridharan, Kimberly Perez, Fateh Bazerbachi, Mari Mino-Kenudson, Brenna Casey, Osama E. Rahma, James M. Cleary, Cristina R. Ferrone
Publikováno v:
Pancreatology. 21:1119-1126
Acinar cell carcinoma (ACC) is a very rare tumor of the exocrine pancreas, representing less than 1% of all pancreatic malignancies. The majority of data regarding ACC are limited to small case series.This is a retrospective study conducted at a larg
Autor:
Carlos Fernández-Hernando, Aurelio Sonzogni, Yasuko Iwakiri, Zhaoli Sun, Alfred Ian Lee, Sandro Sironi, Matthew McConnell, Alexander B Pine, Pietro Andrea Bonaffini, Hua Qing, Xuchen Zhang, Teruo Utsumi, Nao Kawaguchi, Christina Price, Maria Alessio, Lisa Licini, Giulia Previtali, John Hwa, Mario Strazzabosco, Clarissa Valle, Reiichiro Kondo, Michela Seghezzi, Andrew Wang, Xinbo Zhang, Hyung J. Chun
Publikováno v:
Journal of Hepatology
Background and Aims COVID-19 is associated with liver injury and elevated interleukin-6 (IL-6). We hypothesized that IL-6 trans-signaling in liver sinusoidal endothelial cells (LSECs) leads to endotheliopathy (a proinflammatory and procoagulant state
Autor:
Thomas Reiberger, Peter Quehenberger, Ton Lisman, Matthias Pinter, Teresa Binter, Katharina Pomej, Jeannette Becker, Lorenz Balcar, Michael Trauner, Georg Semmler, Lukas Hartl, Bernhard Scheiner, Benedikt Simbrunner, David Bauer, Mattias Mandorfer
Publikováno v:
Liver International
Liver International, 41(9), 2159-2170. Wiley
Liver International, 41(9), 2159-2170. Wiley
Background & Aims While direct oral anticoagulants (DOACs) are increasingly used in patients with liver disease, safety data especially in advanced chronic liver disease (ACLD) are limited. Methods Liver disease patients receiving DOAC treatment (ACL
Autor:
Shubham Jain, Suhas Udgirkar, Pravin Rathi, Ravi Thanage, Sanjay Chandnani, Prasanta Debnath, Samit S Jain, Sujit Nair
Publikováno v:
Pancreas. 50:1236-1242
Methods This was single-center, open-label, randomized trial. Patients who were undergoing ERCP and who were at high risk for the development of PEP were selected for the study. Patients were randomized into 3 treatment groups: diclofenac suppository
Autor:
Minoru Uebayashi, Hiroya Kobayashi, Yasuko Mizuta, Kazuma Kishi, Nobuyuki Ehira, Shoya Shiratori, Shiho Kaneko, Akihisa Nakamura, Kana Matsuda, Masataka Yagisawa
Publikováno v:
BMC Gastroenterology, Vol 21, Iss 1, Pp 1-6 (2021)
Background Olmesartan, which is an angiotensin II receptor blocker, reportedly causes spruelike enteropathy, with intestinal villous atrophy as its typical histopathological finding. Interestingly, collagenous and/or lymphocytic gastritis and colitis
Autor:
Sowmya Tirumalige Ravikumar, Samragni Vasireddy, Padaki Nagaraja Rao, Harshvardhan Tevethia, Rajesh Gupta, Duvvuru Nageshwar Reddy, Pramod Kumar, Anand V. Kulkarni, Mithun Sharma
Publikováno v:
J Clin Exp Hepatol
Background Acute-on-chronic liver failure (ACLF) is a syndrome of acute portal hypertension with high short-term mortality. ACLF patients have low mean arterial pressure (MAP), systemic vascular resistance, and high cardiac output. This, in turn, lea
Autor:
Tatsuya Mitsui, Sotaro Tokunaga, Shintaro Minowa, Daisuke Saito, Jun Miyoshi, Tadakazu Hisamatsu, Akihito Sakuraba, Ryo Ozaki, Mari Hayashida, Miki Miura, Minoru Matsuura
Publikováno v:
JGH Open, Vol 5, Iss 9, Pp 1056-1062 (2021)
JGH Open: An Open Access Journal of Gastroenterology and Hepatology
JGH Open: An Open Access Journal of Gastroenterology and Hepatology
Background and Aim Vedolizumab is a humanized monoclonal antibody that selectively inhibits the migration of gut‐homing memory T cells into the intestinal submucosa by antagonizing the interaction of α4β7 integrin with MAdCAM‐1. Vedolizumab is